1. Hehlmann R., Hochhaus A., Baccarani M. Chronic myeloid leukaemia // Lancet. 2007. Vol. 370, № 9584. P. 342-350.
2. Куликов С.М. et al. Заболеваемость хроническим миелолейкозом в 6 регионах России по данным популяционного исследования 2009-2012 гг. // Терапевтический архив. 2014. Vol. 86, № 7. P. 24-30.
3. Туркина А.Г., Новицкая Н.В. Г.А.К. и др. Регистр больных хроническим миелолейкозом в Российской Федерации: от наблюдательного исследования к оценке эффективности терапии в клинической практике // Клиническая онкогематология. 2017. Vol. 10, № 3. P. 390-401.
4. Hoffmann V.S. et al. Treatment and outcome of 2904 CML patients from the EUTOS population-based registry // Leukemia. Nature Publishing Group, 2017. Vol. 31, № 3. P. 593-601.
5. Fabarius A. et al. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: Long-term observation of 1151 patients from the randomized CML Study IV // Blood. 2011. Vol. 118, № 26. P. 6760-6768.
6. Sokal J.E. et al. Prognostic discrimination in “good-risk” chronic granulocytic leukemia // Blood. 1984. Vol. 63, № 4. P. 789-799.
7. Hasford J. et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: The EUTOS score // Blood. 2011. Vol. 118, № 3. P. 686-692.
8. Marin D., Ibrahim A.R., Goldman J.M. European Treatment and Outcome Study (EUTOS) score for chronic myeloid leukemia still requires more confirmation // Journal of Clinical Oncology. 2011. Vol. 29, № 29. P. 3944-3945.
9. Pfirrmann M. et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia // Leukemia. 2016. Vol. 30, № 1. P. 48-56.
10. Туркина А.Г. et al. Клинические рекомендации по диагностике и лечению хронического миелолейкоза // Клиническая онкогематология. 2017. Vol. 10, № 3. P. 294-316.
11. Baccarani M. et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 // Blood. 2013. Vol. 122, № 6. P. 872-884.
12. Dewald G.W. et al. Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia // Blood. American Society of Hematology, 1998. Vol. 91, № 9. P. 3357-3365.
13. Lima L. et al. Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyond // Cancer. 2011. Vol. 117, № 6. P. 12451252.
14. Kantarjian H.M. et al. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia. // Clin. Cancer Res. 2003. Vol. 9, № 1. P. 160-166.
15. Hughes T. et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results // Blood. 2006. Vol. 108, № 1. P. 28-37.
16. Branford S., Hughes T.P., Rudzki Z. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics // Br. J. Haematol. Blackwell Publishing Ltd., 1999. Vol. 107, № 3. P. 587-599.
17. Wang L. et al. Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia // Br. J. Haematol. 2002. Vol. 118, № 3. P. 771-777.
18. Hoffmann V.S. et al. Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia // J. Cancer Res. Clin. Oncol. Springer Verlag, 2017. Vol. 143, № 7. P. 13111318.
19. Hochhaus A. et al. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia // N. Engl. J. Med. 2017. Vol. 376, № 10. P. 917-927.
20. Talpaz M. et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study // Blood. 2002. Vol. 99, № 6. P. 1928-1937.
21. Kantarjian H.M. et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosomepositive chronic myelogenous leukemia in blast phase. // Blood. 2002. Vol. 99, № 10. P. 3547-3553.
22. Sawyers C.L. et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. // Blood. 2002. Vol. 99, № 10. P. 3530-3539.
23. Palandri F. et al. The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: The GIMEMA CML Working Party experience after a 7-year follow-up // Haematologica. 2009. Vol. 94, № 2. P. 205-212.
24. O’Brien S.G. et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia // N. Engl. J. Med. 2003. Vol. 348, № 11. P. 994-1004.
25. Hochhaus A. et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial // Leukemia. Nature Publishing Group, 2016. Vol. 30, № 5. P. 1044-1054.
26. Cortes J. et al. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial // J. Clin. Oncol. 2016. Vol. 34, № 20. P. 2333-2341.
27. Kantarjian H. et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up // Blood. 2009. Vol. 113, № 25. P. 6322-6329.
28. Cortes J. et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis // Blood. 2007. Vol. 109, № 8. P. 3207-3213.